AIM
ALNY icon

ARK Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

ARK Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-19,362
Closed -$1.91M – 203
2018
Q2 		$1.91M Buy
19,362
+8,250
+74% +$818K 0.07% 92
2018
Q1 		$1.32M Buy
11,112
+9,014
+430% +$1.16M 0.07% 97
2017
Q4 		$267K Sell
2,098
-6,976
-77% -$877K 0.02% 134
2017
Q3 		$1.07M Buy
9,074
+3,798
+72% +$324K 0.13% 84
2017
Q2 		$421K Sell
5,276
-948
-15% -$60.6K 0.08% 86
2017
Q1 		$319K Sell
6,224
-117,506
-95% -$5.43M 0.09% 73
2016
Q4 		$4.63M Buy
+123,730
New +$5.18M 1.69% 21

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

ARK Investment Management's ALNY Position: Q3 2018 in Review

ARK Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2018, closing a stake of 19,362 shares — an estimated $1.91M sold.

ARK Investment Management first reported a position in ALNY in Q4 2016 and held it in 7 quarters. The position peaked at $4.63M in Q4 2016. 305 funds tracked by Wall St. Rank hold ALNY as of Q3 2018.

  • ARK Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • ARK Investment Management sold 19,362 Alnylam Pharmaceuticals shares in Q3 2018, an estimated $1.91M.
  • ARK Investment Management first reported a position in Alnylam Pharmaceuticals in Q4 2016 and held it in 7 quarters.
  • ARK Investment Management's Alnylam Pharmaceuticals position peaked at $4.63M in Q4 2016.
  • 305 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2018.

Based on ARK Investment Management's 13F filing for Q3 2018, filed 7 Nov 2018.